FDA Product Code OCC: Respiratory Virus Panel Nucleic Acid Assay System
Under FDA product code OCC, respiratory virus panel nucleic acid assay systems are cleared for multiplex detection of respiratory viral pathogens.
These assays simultaneously identify multiple common respiratory viruses — including influenza A/B, RSV, parainfluenza, adenovirus, and human metapneumovirus — from a single respiratory specimen, enabling rapid and comprehensive viral diagnosis for patient cohorting and treatment decisions.
OCC devices are Class II medical devices, regulated under 21 CFR 866.3980 and reviewed by the FDA Microbiology panel.
Leading manufacturers include Luminex Molecular Diagnostics, Inc., Cepheid and Nanosphere, Inc..
FDA 510(k) Cleared Respiratory Virus Panel Nucleic Acid Assay System Devices (Product Code OCC)
About Product Code OCC - Regulatory Context
510(k) Submission Activity
80 total 510(k) submissions under product code OCC since 2008, with 79 receiving FDA clearance (average review time: 99 days).
Submission volume has declined in recent years - 2 submissions in the last 24 months compared to 3 in the prior period.
FDA 510(k) Review Time - OCC Product Code
Recent submissions under OCC have taken an average of 155 days to reach a decision - up from 97 days historically. Manufacturers should account for longer review timelines in current project planning.
OCC devices are reviewed by the Microbiology panel. Browse all Microbiology devices →